Key result
Cardiologist-ordered genetic testing in cardiomyopathy yields variants of uncertain significance in ~61% of patients.
Why the study?
Mainstream cardiac genetic testing ordered by cardiologists may expand access but the operational burden and infrastructure requirements for safe scale-up were not quantified.
Cohort (n=482)
Mainstream cardiologist-delivered genetic testing for cardiomyopathy requires dedicated infrastructure for variant surveillance, recontacting, and managing high-risk genotypes and carrier findings.
High VUS rates in cardiomyopathy testing warrant dedicated reclassification infrastructure; leaves open optimal mainstream cardiologist delivery without prospective validation.
BACKGROUND: Mainstream cardiac genetic testing, in which the treating cardiologist orders and returns multigene panel results without a traditional genetic counseling session, may expand access, but no mainstream program has quantified the operational burden. We quantified high-risk genotypes, variant reclassification, and carrier findings in a mainstream cardiomyopathy testing program to characterize the infrastructure required for safe scale-up. METHODS: We retrospectively analyzed 482 consecutive patients with dilated cardiomyopathy (n=338), nondilated left ventricular cardiomyopathy (n=84), or hypertrophic cardiomyopathy (n=60) who underwent multigene panel testing ordered by cardiologists at the Broderick Cardiomyopathy Program (January 2022 to February 2026). Variant classifications used each laboratory's most current interpretation. RESULTS: ) requiring genotype-specific management; (2) 8 of 12 reclassified variants (12/743 total, 1.6%) crossed the pathogenic/likely pathogenic threshold, including 7 variant of uncertain significance-to- pathogenic/likely pathogenic upgrades converting nondiagnostic patients to genotype-positive; and (3) carrier findings comprised 26 of 121 pathogenic/likely pathogenic variants (21.5%), inflating apparent yield to 23.7% if carrier findings were not distinguished from diagnostic results based on gene inheritance pattern. Variants of uncertain significance were reported in 295 patients (61.2%). CONCLUSIONS: These data identify 5 capabilities that support safe mainstream scale-up: high-risk genotype pathways for the 1 in 5 diagnostic patients with a high-risk variant, variant surveillance with recontact capacity for the 1 in 60 patients affected by actionable reclassification, recognition of gene inheritance pattern for the 1 in 19 patients with a carrier finding, a defined referral pathway to medical genetics, and standardized family screening infrastructure for all result categories.
No takes yet. Share an insight, caveat, or question.
Kiamanesh et al. (2026) conducted a cohort in Cardiomyopathy (n=482). Cardiologist-delivered multigene panel testing was evaluated on High-risk genotypes, variant reclassification, and carrier findings. In 482 patients with cardiomyopathy undergoing cardiologist-delivered genetic testing, variants of uncertain significance were reported in 61.2% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: